60 Degrees Pharmaceuticals (SCTP) investor relations material

Company overview and business model

• Specialty pharmaceutical company focused on developing and commercializing therapies for infectious diseases, with a primary product, Arakoda, approved for malaria prevention since 2019.

• Pipeline includes products for vector-borne, fungal, and viral diseases, leveraging Tafenoquine and Celgosivir, and botanical extracts from Australian Chestnut Trees.

• Operates a majority-owned Australian subsidiary holding ex-U.S. sub-licensing rights and collaborates with public and academic partners to reduce development costs.

• Strategy centers on expanding Arakoda sales, clinical trials for new indications, and repositioning small molecule therapeutics with established safety profiles.

Financial performance and metrics

• Raised capital through at-the-market (ATM) offerings in 2025 and 2026, generating net proceeds of $1.24M and $2.54M, respectively, at average prices around $2.50 per share.

• Implemented a 1:4 reverse stock split in January 2026 to regain Nasdaq compliance after a delisting notice, with subsequent notification of compliance in February 2026.

• As of August 13, 2026, 3,516,988 shares of common stock were outstanding.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of registered securities by selling stockholders; proceeds from warrant exercises, if any, will be used for general corporate purposes.

• Net proceeds from recent ATM offerings are allocated to sales, marketing, and ongoing clinical and preclinical research.